<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>64</volume><submitter>Haraldsdottir A</submitter><pubmed_abstract>&lt;h4>Background and purpose&lt;/h4>Organised mammography screening reduces breast cancer mortality by 30-40% in women aged 50-69. Despite limited evidence for women aged 40-49, screening guidelines are trending toward younger ages. Iceland has offered biennial screening to women aged 40-69 since 1987. This study compares screening quality indicators and tumour characteristics between women aged 40-49 and 50-69 from 1990 to 2020. Patient/material and methods: Screening-related data were obtained from the Icelandic Breast Cancer Screening Program, and breast cancer diagnoses and tumour characteristics were sourced from the Icelandic Cancer Registry.&lt;h4>Results&lt;/h4>In total, 84,677 women aged 40-69 years attended 455,532 organised screening sessions in Iceland over a 30-year period. Women aged 40-49 years demonstrated higher recall rates (4.9% vs. 3.5%) and lower participation rates (60.7% vs. 61.5%), lower breast cancer detection rates (2.1 vs. 6.0/1,000), and lower episode sensitivity (54.8% vs. 70.5%), compared to those aged 50-69 years. Among screen-detected cases, women aged 40-49 years exhibited a higher proportion of tumours larger than 20 mm (29.7% vs. 21.7%), more lymph node positivity (41.2% vs. 28.2%) and higher human epidermal growth factor receptor 2 (HER2) positivity (18.6% vs. 11.8%), compared to those aged 50-69 years.&lt;h4>Interpretation&lt;/h4>The disparity in breast cancer screening performances between the age groups may reflect unmodifiable factors in younger women. The presence of advanced tumour characteristics among women aged 40-49 years who attended screening indicates the importance of early detection for improving prognosis.</pubmed_abstract><journal>Acta oncologica (Stockholm, Sweden)</journal><pagination>1061-1070</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12372527</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Thirty years of population-based breast cancer screening in Iceland: a comparison of quality indicators and tumour characteristics between women aged 40-49 and 50-69 years.</pubmed_title><pmcid>PMC12372527</pmcid><pubmed_authors>Tryggvadottir L</pubmed_authors><pubmed_authors>Agustsson AI</pubmed_authors><pubmed_authors>Haraldsdottir A</pubmed_authors><pubmed_authors>Birgisson H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Thirty years of population-based breast cancer screening in Iceland: a comparison of quality indicators and tumour characteristics between women aged 40-49 and 50-69 years.</name><description>&lt;h4>Background and purpose&lt;/h4>Organised mammography screening reduces breast cancer mortality by 30-40% in women aged 50-69. Despite limited evidence for women aged 40-49, screening guidelines are trending toward younger ages. Iceland has offered biennial screening to women aged 40-69 since 1987. This study compares screening quality indicators and tumour characteristics between women aged 40-49 and 50-69 from 1990 to 2020. Patient/material and methods: Screening-related data were obtained from the Icelandic Breast Cancer Screening Program, and breast cancer diagnoses and tumour characteristics were sourced from the Icelandic Cancer Registry.&lt;h4>Results&lt;/h4>In total, 84,677 women aged 40-69 years attended 455,532 organised screening sessions in Iceland over a 30-year period. Women aged 40-49 years demonstrated higher recall rates (4.9% vs. 3.5%) and lower participation rates (60.7% vs. 61.5%), lower breast cancer detection rates (2.1 vs. 6.0/1,000), and lower episode sensitivity (54.8% vs. 70.5%), compared to those aged 50-69 years. Among screen-detected cases, women aged 40-49 years exhibited a higher proportion of tumours larger than 20 mm (29.7% vs. 21.7%), more lymph node positivity (41.2% vs. 28.2%) and higher human epidermal growth factor receptor 2 (HER2) positivity (18.6% vs. 11.8%), compared to those aged 50-69 years.&lt;h4>Interpretation&lt;/h4>The disparity in breast cancer screening performances between the age groups may reflect unmodifiable factors in younger women. The presence of advanced tumour characteristics among women aged 40-49 years who attended screening indicates the importance of early detection for improving prognosis.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-05-08T10:50:05.812Z</modification><creation>2026-05-03T03:05:48.868Z</creation></dates><accession>S-EPMC12372527</accession><cross_references><pubmed>40814243</pubmed><doi>10.2340/1651-226X.2025.44090</doi></cross_references></HashMap>